ERBB2 and breast neoplasm: Pre-clinically, BH has also been combined with αCTLA4 and αPD1 to treat neuroblastoma 14, αPD-L1 to treat triple negative and HER2 breast tumors 13, αCD40 agonist to treat melanoma 15, and αPD-1 to treat 4T1 breast tumors 16.